A summary of the evidence supporting the effect of this protocol is below.
A total of 241 patients between September 2005 and August 2010 were randomised into 4 arms: A (3 weekly docetaxel/gemcitabine), B (3 weekly paclitaxel/gemcitabine), C (weekly docetaxel/gemcitabine) and D (weekly paclitaxel and gemcitabine). Time to progression was similar in all 4 arms.r
Time-to-progression by treatment arm (gemcitabine+docetaxel vs gemcitabine+paclitaxel)r
© BMC Cancer 2013
Efficacy data from retrospective study of weekly gemcitabine/paclitaxel in metastatic breast cancerr
|Median overall survival
|Median progression-free survival